BACKGROUND:Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. METHODS: We conducted a randomized trial of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1-serodiscordant heterosexual couples from Kenya and Uganda. The HIV-1-seronegative partner in each couple was randomly assigned to one of three study regimens--once-daily tenofovir (TDF), combination tenofovir-emtricitabine (TDF-FTC), or matching placebo--and followed monthly for up to 36 months. At enrollment, the HIV-1-seropositive partners were not eligible for antiretroviral therapy, according to national guidelines. All couples received standard HIV-1 treatment and prevention services. RESULTS:We enrolled 4758 couples, of whom 4747 were followed: 1584 randomly assigned to TDF, 1579 to TDF-FTC, and 1584 toplacebo. For 62% of the couples followed, the HIV-1-seronegative partner was male. Among HIV-1-seropositive participants, the median CD4 count was 495 cells per cubic millimeter (interquartile range, 375 to 662). A total of 82 HIV-1 infections occurred in seronegative participants during the study, 17 in the TDF group (incidence, 0.65 per 100 person-years), 13 in the TDF-FTC group (incidence, 0.50 per 100 person-years), and 52 in the placebo group (incidence, 1.99 per 100 person-years), indicating a relative reduction of 67% in the incidence of HIV-1 with TDF (95% confidence interval [CI], 44 to 81; P<0.001) and of 75% with TDF-FTC (95% CI, 55 to 87; P<0.001). Protective effects of TDF-FTC and TDF alone against HIV-1 were not significantly different (P=0.23), and both study medications significantly reduced the HIV-1 incidence among both men and women. The rate of serious adverse events was similar across the study groups. Eight participants receiving active treatment were found to have been infected with HIV-1 at baseline, and among these eight, antiretroviral resistance developed in two during the study. CONCLUSIONS:Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women. (Funded by the Bill and Melinda Gates Foundation; Partners PrEP ClinicalTrials.gov number, NCT00557245.).
RCT Entities:
BACKGROUND: Antiretroviral preexposure prophylaxis is a promising approach for preventing humanimmunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. METHODS: We conducted a randomized trial of oral antiretroviral therapy for use as preexposure prophylaxis among HIV-1-serodiscordant heterosexual couples from Kenya and Uganda. The HIV-1-seronegative partner in each couple was randomly assigned to one of three study regimens--once-daily tenofovir (TDF), combination tenofovir-emtricitabine (TDF-FTC), or matching placebo--and followed monthly for up to 36 months. At enrollment, the HIV-1-seropositive partners were not eligible for antiretroviral therapy, according to national guidelines. All couples received standard HIV-1 treatment and prevention services. RESULTS: We enrolled 4758 couples, of whom 4747 were followed: 1584 randomly assigned to TDF, 1579 to TDF-FTC, and 1584 to placebo. For 62% of the couples followed, the HIV-1-seronegative partner was male. Among HIV-1-seropositiveparticipants, the median CD4 count was 495 cells per cubic millimeter (interquartile range, 375 to 662). A total of 82 HIV-1 infections occurred in seronegative participants during the study, 17 in the TDF group (incidence, 0.65 per 100 person-years), 13 in the TDF-FTC group (incidence, 0.50 per 100 person-years), and 52 in the placebo group (incidence, 1.99 per 100 person-years), indicating a relative reduction of 67% in the incidence of HIV-1 with TDF (95% confidence interval [CI], 44 to 81; P<0.001) and of 75% with TDF-FTC (95% CI, 55 to 87; P<0.001). Protective effects of TDF-FTC and TDF alone against HIV-1 were not significantly different (P=0.23), and both study medications significantly reduced the HIV-1 incidence among both men and women. The rate of serious adverse events was similar across the study groups. Eight participants receiving active treatment were found to have been infected with HIV-1 at baseline, and among these eight, antiretroviral resistance developed in two during the study. CONCLUSIONS: Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women. (Funded by the Bill and Melinda Gates Foundation; Partners PrEP ClinicalTrials.gov number, NCT00557245.).
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit Journal: Lancet Infect Dis Date: 2011-07-27 Impact factor: 25.071
Authors: Nelly R Mugo; Renee Heffron; Deborah Donnell; Anna Wald; Edwin O Were; Helen Rees; Connie Celum; James N Kiarie; Craig R Cohen; Kayitesi Kayintekore; Jared M Baeten Journal: AIDS Date: 2011-09-24 Impact factor: 4.177
Authors: C Celum; A Wald; J R Lingappa; A S Magaret; R S Wang; N Mugo; A Mujugira; J M Baeten; J I Mullins; J P Hughes; E A Bukusi; C R Cohen; E Katabira; A Ronald; J Kiarie; C Farquhar; G J Stewart; J Makhema; M Essex; E Were; K H Fife; G de Bruyn; G E Gray; J A McIntyre; R Manongi; S Kapiga; D Coetzee; S Allen; M Inambao; K Kayitenkore; E Karita; W Kanweka; S Delany; H Rees; B Vwalika; W Stevens; M S Campbell; K K Thomas; R W Coombs; R Morrow; W L H Whittington; M J McElrath; L Barnes; R Ridzon; L Corey Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Oliver Laeyendecker; Charla Henson; Ronald H Gray; Ruby H-N Nguyen; Bobbi Jo Horne; Maria J Wawer; David Serwadda; Noah Kiwanuka; Rhoda Ashley Morrow; Wayne Hogrefe; Thomas C Quinn Journal: J Clin Microbiol Date: 2004-04 Impact factor: 5.948
Authors: Andrew Mujugira; Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; Linda Barnes; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Lara Kidoguchi; Dana Panteleeff; Meighan Krows; Heena Shah; Jennifer Revall; Susan Morrison; Lisa Ondrejcek; Charlotte Ingram; Robert W Coombs; Jairam R Lingappa; Connie Celum Journal: PLoS One Date: 2011-10-05 Impact factor: 3.240
Authors: Michael E Newcomb; Kevin Moran; Brian A Feinstein; Emily Forscher; Brian Mustanski Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Patrick S Sullivan; Robertino Mera Giler; Farah Mouhanna; Elizabeth S Pembleton; Jodie L Guest; Jeb Jones; Amanda D Castel; Howa Yeung; Michael Kramer; Scott McCallister; Aaron J Siegler Journal: Ann Epidemiol Date: 2018-06-22 Impact factor: 3.797
Authors: Erika G Martin; Roderick H MacDonald; Daniel E Gordon; Carol-Ann Swain; Travis O'Donnell; John Helmeset; Adenantera Dwicaksono; James M Tesoriero Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: Briana Nixon; Thomas Jandl; Ryan S Teller; Ekaterina Taneva; Yanhua Wang; Umadevi Nagaraja; Patrick F Kiser; Betsy C Herold Journal: Antimicrob Agents Chemother Date: 2013-12-09 Impact factor: 5.191